See the published version of this preprint at Alzheimer's Research and Therapy.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Inhee Mook-Jung
Seoul National University College of Medicine
Corresponding Author
ORCiD: https://orcid.org/0000-0001-7085-4085
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Alzheimer's disease (AD) is an irreversible neurodegenerative disease characterized by the hallmark finding of cerebral amyloid deposition. Many researchers have tried to predict the existence of cerebral amyloid deposition by using easily accessible blood plasma samples, but the effectiveness of such strategies remains controversial.
Methods: We developed a new multiplex kit, the QPLEXTM Alz plus assay kit, which uses proteomics-based blood biomarkers to prescreen for cerebral amyloid deposition. A total of 300 participants who underwent Pittsburgh compound B (PiB)-positron emission tomography (PET) which allows imaging of cerebral amyloid deposition were included in this study. We compared the levels of QPLEXTM biomarkers between patients who were classified as PiB-negative or PiB-positive, regardless of their cognitive function. Logistic regression analysis followed by receiver operating characteristic (ROC) curve analysis was performed. The kit accuracy was tested using a randomized sample selection method.
Results: The results obtained using our assay kit reached 89.1% area under curve (AUC) with 80.0% sensitivity and 83.0% specificity. Further validation of the QPLEXTM Alz plus assay kit using a randomized sample selection method showed an average accuracy of 81.5%.
Conclusions: Our QPLEXTM Alz plus assay kit provides preliminary evidence that it can be used as blood marker to predict cerebral amyloid deposition but independent validation is needed.
Keywords
Alzheimer’s disease, Pittsburgh compound B, cerebral amyloid deposition, blood-based biomarker, QPLEXTM Alz plus assay
Figure 1
Figure 1
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
- Rev3TableS1.docx
- Rev3SupplementaryFig1.tif
Supplementary Fig. 1. Comparison of PiB- vs. PiB+ among CN or MCI. (A) Logistic regression analysis followed by ROC curve analysis among the CN group and comparison of ROC curve analysis. (B) Logistic regression analysis followed by ROC curve analysis among the MCI group and comparison of ROC curve analysis. AUC, area under curve; PV, predictive values; SE, standard error; CI, confidence interval.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Alzheimer's Research and Therapy.
Version 3
Posted 18 Dec, 2020
No community comments so far
Editorial decision: Accept
On 30 Nov, 2020
Editor assigned
On 29 Nov, 2020
Submission checks complete
On 29 Nov, 2020
Editor invited
On 29 Nov, 2020
Version (no preprint)
Posted 23 Nov, 2020
Editorial decision: Minor Revision
On 23 Nov, 2020
Editor assigned
On 22 Nov, 2020
Submission checks complete
On 22 Nov, 2020
Editor invited
On 22 Nov, 2020
This version was not preprinted
No comments provided
Editorial decision: Minor Revision
On 30 Oct, 2020
Editor assigned
On 24 Sep, 2020
Submission checks complete
On 23 Sep, 2020
Editor invited
On 23 Sep, 2020
No comments provided
Editorial decision: Major Revision
On 02 Aug, 2020
Editor assigned
On 02 Jul, 2020
Editor invited
On 01 Jul, 2020
Submission checks complete
On 26 Jun, 2020
First submitted
On 25 Jun, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cognitive Neuroscience
Learn more about our company.
See the published version of this preprint at Alzheimer's Research and Therapy.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Inhee Mook-Jung
Seoul National University College of Medicine
Corresponding Author
ORCiD: https://orcid.org/0000-0001-7085-4085
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Alzheimer's Research and Therapy.
Version 3
Posted 18 Dec, 2020
No community comments so far
Editorial decision: Accept
On 30 Nov, 2020
Editor assigned
On 29 Nov, 2020
Submission checks complete
On 29 Nov, 2020
Editor invited
On 29 Nov, 2020
Version (no preprint)
Posted 23 Nov, 2020
Editorial decision: Minor Revision
On 23 Nov, 2020
Editor assigned
On 22 Nov, 2020
Submission checks complete
On 22 Nov, 2020
Editor invited
On 22 Nov, 2020
This version was not preprinted
No comments provided
Editorial decision: Minor Revision
On 30 Oct, 2020
Editor assigned
On 24 Sep, 2020
Submission checks complete
On 23 Sep, 2020
Editor invited
On 23 Sep, 2020
No comments provided
Editorial decision: Major Revision
On 02 Aug, 2020
Editor assigned
On 02 Jul, 2020
Editor invited
On 01 Jul, 2020
Submission checks complete
On 26 Jun, 2020
First submitted
On 25 Jun, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cognitive Neuroscience
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Alzheimer's Research and Therapy.
Background: Alzheimer's disease (AD) is an irreversible neurodegenerative disease characterized by the hallmark finding of cerebral amyloid deposition. Many researchers have tried to predict the existence of cerebral amyloid deposition by using easily accessible blood plasma samples, but the effectiveness of such strategies remains controversial.
Methods: We developed a new multiplex kit, the QPLEXTM Alz plus assay kit, which uses proteomics-based blood biomarkers to prescreen for cerebral amyloid deposition. A total of 300 participants who underwent Pittsburgh compound B (PiB)-positron emission tomography (PET) which allows imaging of cerebral amyloid deposition were included in this study. We compared the levels of QPLEXTM biomarkers between patients who were classified as PiB-negative or PiB-positive, regardless of their cognitive function. Logistic regression analysis followed by receiver operating characteristic (ROC) curve analysis was performed. The kit accuracy was tested using a randomized sample selection method.
Results: The results obtained using our assay kit reached 89.1% area under curve (AUC) with 80.0% sensitivity and 83.0% specificity. Further validation of the QPLEXTM Alz plus assay kit using a randomized sample selection method showed an average accuracy of 81.5%.
Conclusions: Our QPLEXTM Alz plus assay kit provides preliminary evidence that it can be used as blood marker to predict cerebral amyloid deposition but independent validation is needed.
Figure 1
Figure 1
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
- Rev3TableS1.docx
- Rev3SupplementaryFig1.tif
Supplementary Fig. 1. Comparison of PiB- vs. PiB+ among CN or MCI. (A) Logistic regression analysis followed by ROC curve analysis among the CN group and comparison of ROC curve analysis. (B) Logistic regression analysis followed by ROC curve analysis among the MCI group and comparison of ROC curve analysis. AUC, area under curve; PV, predictive values; SE, standard error; CI, confidence interval.
Loading...